Converting Oral Estradiol to Injectable Estradiol
Start with injectable estradiol cypionate or valerate at 3-4 mg weekly (subcutaneous or intramuscular) when converting from oral estradiol 2 mg twice daily (4 mg total daily), then titrate based on serum estradiol levels drawn mid-cycle.
Dosing Rationale
The current oral dose of 4 mg daily estradiol results in significantly elevated estrone levels due to first-pass hepatic metabolism, which may not translate to equivalent systemic estradiol exposure 1. Recent multicenter data demonstrates that the majority of patients achieve guideline-recommended estradiol concentrations (100-200 pg/mL) with injectable doses of 4 mg weekly or less 2. Among 562 patients studied, the median dose achieving target levels was only 4.0 mg weekly (IQR 3.0-5.0 mg) 2.
Key Conversion Points:
- Do not use a 1:1 conversion ratio - oral estradiol undergoes extensive first-pass metabolism creating disproportionate estrone elevation
- Injectable estradiol provides more stable, physiologic estradiol levels without excessive estrone
- Current guidelines suggesting 5-30 mg every 2 weeks or 2-10 mg weekly are too high and consistently produce supraphysiologic levels 3, 4, 2
Recommended Conversion Protocol
Initial dosing:
- Start injectable estradiol cypionate or valerate at 3-4 mg weekly
- Either subcutaneous or intramuscular administration is equally effective 2
- No significant difference between cypionate and valerate esters 2
Monitoring:
- Check serum estradiol levels 3-4 days after injection (mid-cycle) after 4-6 weeks on stable dosing
- Target estradiol concentration: 100-200 pg/mL per standard guidelines 2
- Also monitor testosterone suppression if that is a treatment goal
Titration:
- If estradiol <100 pg/mL: increase by 1 mg weekly increments
- If estradiol >200 pg/mL: decrease by 1 mg weekly increments
- Most patients will not require doses above 5 mg weekly 4, 2
Critical Pitfalls to Avoid
Supraphysiologic dosing: The most common error is starting too high based on older guideline recommendations. Data shows that doses ≥5 mg weekly frequently result in estradiol levels >200 pg/mL (often >300-400 pg/mL), which exceeds physiologic ranges and may increase risks without additional benefit 3, 4, 2.
Timing of laboratory draws: Estradiol levels fluctuate significantly across the injection cycle. Always document timing relative to last injection - levels drawn immediately before the next dose will be artificially low, while levels drawn 1-2 days post-injection will be artificially high 2. Mid-cycle (3-4 days post-injection for weekly dosing) provides the most representative assessment.
Assuming route/ester differences: There are no clinically significant differences in estradiol concentrations achieved between intramuscular vs subcutaneous administration, or between cypionate vs valerate esters at equivalent doses 2. Choose based on patient preference and availability.
Additional Considerations
If the patient requires progestin for endometrial protection (intact uterus), continue current progestin regimen unchanged during the conversion. The progestin dosing does not need adjustment when switching estradiol routes 5.
Transdermal alternative: If injectable estradiol is unavailable or refused, transdermal patches releasing 50-100 μg daily represent the preferred alternative over continuing oral estradiol, as they avoid first-pass hepatic metabolism and provide more physiologic hormone levels 5, 6.
The conversion should be direct - stop oral estradiol and start injectable estradiol on the same day. No tapering or overlap period is necessary.